Drug Pricing: Page 3
-
Sponsored by Phil
Harnessing data to improve patient access and optimize gross-to-net
Discover the data and metrics you should be tracking to evaluate patient access.
March 6, 2023 -
Lilly to lower insulin prices by 70%
The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.
By Jonathan Gardner • March 1, 2023 -
Trendline
Drug pricing
Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.
By BioPharma Dive staff -
Sponsored by Phil
Harnessing data to improve patient access and optimize gross-to-net
Discover the data and metrics you should be tracking to evaluate patient access.
Feb. 27, 2023 -
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Eisai and Biogen have data showing Leqembi slows cognitive decline, but CMS won’t budge until FDA converts its approval from accelerated to full.
By Jonathan Gardner • Feb. 23, 2023 -
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
The proposed model could help state Medicaid agencies explore different kinds of outcomes-based payment schemes, but may come too late to prepare for the first sickle cell gene therapy.
By Ned Pagliarulo • Feb. 21, 2023 -
Deep Dive // Patent thickets
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines.
By Jonathan Gardner • Feb. 21, 2023 -
CMS plans trio of experiments aimed at lowering drug costs
The pilot programs could allow adjusted payments for drugs cleared under accelerated approval and help states manage the costs of gene therapies.
By Christopher Newman • Feb. 15, 2023 -
Medicare to collect drug price rebates starting in 2025
CMS laid out how it plans to implement a key provision of the Inflation Reduction Act, which requires drugmakers to pay rebates on price hikes within Medicare that are greater than inflation.
By Christopher Newman • Feb. 10, 2023 -
In address to Congress, Biden touts drug pricing law and pushes insulin cost caps
In his State of the Union speech, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the high cost of insulin.
By Kristin Jensen • Feb. 8, 2023 -
Patent thickets
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
The world’s best-selling drug will face pricing pressure as rivals try to steal share from AbbVie’s $20 billion-a-year flagship product in the U.S.
By Jonathan Gardner • Jan. 31, 2023 -
Moderna draws more lawmaker criticism for COVID vaccine pricing plan
Senators Warren and Welch urged the biotech to reconsider a planned price hike to between $110 and $130 a dose, and sought answers to a long list of questions.
By Kristin Jensen • Jan. 26, 2023 -
Pfizer expands not-for-profit pledge to include more medicines
The pharma is now committing to providing all of the roughly 500 products in its portfolio, including antibiotics and cancer drugs, to 45 lower-income countries.
By Kristin Jensen • Jan. 17, 2023 -
California files suit against PBMs over insulin prices
The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.
By Hailey Mensik • Jan. 13, 2023 -
HHS lays out timing for drug price negotiations
The agency will begin discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023.
By Christopher Newman • Jan. 11, 2023 -
Sanders to target healthcare costs as leader of influential Senate committee
The longtime congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy forums.
By Sydney Halleman • Jan. 9, 2023 -
New Alzheimer's drugs
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.
By Ned Pagliarulo • Jan. 6, 2023 -
Pharma companies boost drug prices to start year, but hikes lag inflation
Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.
By Jonathan Gardner • Jan. 3, 2023 -
Gene therapy approval won, Bluebird takes on next challenge: selling it
The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
By Ned Pagliarulo • Dec. 12, 2022 -
Sponsored by First Republic Bank
Life science investment outlook: thinking beyond the pandemic
Learn about the investment landscape for life science companies, heading into 2023.
Dec. 12, 2022 -
Sanders poised to lead Senate health committee
The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.
By Susan Kelly • Nov. 28, 2022 -
FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar
Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.
By Christopher Newman • Nov. 18, 2022 -
Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says
The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.
By Rebecca Pifer • Nov. 16, 2022 -
EQRx redraws ‘radical’ drug pricing plans for first two drugs
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.
By Jonathan Gardner • Nov. 10, 2022 -
Pharma earnings outline drug law’s looming impact on sales, development
While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.
By Christopher Newman • Nov. 9, 2022 -
Sponsored by GoodRx
Inflation Reduction Act: What are the healthcare implications?
The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.
Oct. 31, 2022